FDA approval establishes durvalumab plus BCG induction and maintenance as a new immunotherapy-based option for BCG-naïve, high-risk NMIBC following TURBT, potentially redefining the frontline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results